0	11	Differences	difference	NNS
12	14	in	in	IN
15	30	phosphorylation	phosphorylation	NN
31	33	of	of	IN
34	37	the	the	DT
38	43	IL-2R	il-2r	NN
44	54	associated	associated	JJ
55	63	JAK/STAT	JAK/STAT	NNP
64	72	proteins	protein	NNS
73	80	between	between	IN
81	90	HTLV-I(+)	htlv-i(+)	JJ
90	91	,	,	,
92	108	IL-2-independent	il-2-independent	JJ
109	112	and	and	CC
113	127	IL-2-dependent	il-2-dependent	JJ
128	132	cell	cell	NN
133	138	lines	line	NNS
139	142	and	and	CC
143	153	uncultured	uncultured	JJ
154	162	leukemic	leukemic	JJ
163	168	cells	cell	NNS
169	173	from	from	IN
174	182	patients	patient	NNS
183	187	with	with	IN
188	193	adult	adult	JJ
194	200	T-cell	t-cell	NN
201	218	lymphoma/leukemia	lymphoma/leukemia	NN
218	219	.	.	.

221	223	To	to	TO
224	233	determine	determine	VB
234	244	activation	activation	NN
245	251	status	status	NN
252	254	of	of	IN
255	258	the	the	DT
259	275	IL-2R-associated	il-2r-associated	JJ
276	277	(	(	(
277	285	Jak/STAT	Jak/STAT	NNP
285	286	)	)	)
287	294	pathway	pathway	NN
295	297	in	in	IN
298	301	the	the	DT
302	308	HTLV-I	HTLV-I	NNP
309	317	infected	infected	JJ
318	323	cells	cell	NNS
323	324	,	,	,
325	327	we	we	PRP
328	336	examined	examine	VBD
337	345	tyrosine	tyrosine	NN
346	361	phosphorylation	phosphorylation	NN
362	364	of	of	IN
365	369	Jak3	Jak3	NNP
369	370	,	,	,
371	376	STAT3	STAT3	NNP
376	377	,	,	,
378	381	and	and	CC
382	387	STAT5	stat5	NN
388	390	in	in	IN
391	398	several	several	JJ
399	408	HTLV-I(+)	htlv-i(+)	JJ
409	415	T-cell	t-cell	NN
416	421	lines	line	NNS
422	425	and	and	CC
426	428	in	in	IN
429	439	uncultured	uncultured	JJ
440	448	leukemic	leukemic	JJ
449	450	T	t	NN
451	456	cells	cell	NNS
457	465	isolated	isolate	VBN
466	470	from	from	IN
471	479	patients	patient	NNS
480	484	with	with	IN
485	490	adult	adult	JJ
491	497	T-cell	t-cell	NN
498	515	lymphoma/leukemia	lymphoma/leukemia	NN
516	517	(	(	(
517	521	ATLL	ATLL	NNP
521	522	)	)	)
522	523	.	.	.

524	536	Constitutive	constitutive	JJ
537	542	basal	basal	JJ
543	558	phosphorylation	phosphorylation	NN
559	561	of	of	IN
562	566	Jak3	Jak3	NNP
567	570	and	and	CC
570	571	,	,	,
572	579	usually	usually	RB
579	580	,	,	,
581	586	STAT3	STAT3	NNP
587	590	and	and	CC
591	596	STAT5	STAT5	NNP
597	600	was	be	VBD
601	609	detected	detect	VBN
610	612	in	in	IN
613	616	all	all	DT
617	621	four	four	CD
622	638	IL-2-independent	il-2-independent	JJ
639	643	cell	cell	NN
644	649	lines	line	NNS
650	656	tested	test	VBN
656	657	,	,	,
658	661	but	but	CC
662	664	in	in	IN
665	669	none	none	NN
670	672	of	of	IN
673	676	the	the	DT
677	682	three	three	CD
683	697	IL-2-dependent	il-2-dependent	JJ
698	702	cell	cell	NN
703	708	lines	line	NNS
708	709	.	.	.

710	719	Similarly	similarly	RB
719	720	,	,	,
721	726	there	there	EX
727	730	was	be	VBD
731	733	no	no	DT
734	744	detectable	detectable	JJ
745	750	basal	basal	JJ
751	766	phosphorylation	phosphorylation	NN
767	769	of	of	IN
770	774	Jak3	Jak3	NNP
775	778	and	and	CC
779	784	STAT5	STAT5	NNP
785	787	in	in	IN
788	791	the	the	DT
792	800	leukemic	leukemic	JJ
801	806	cells	cell	NNS
807	811	from	from	IN
812	816	ATLL	ATLL	NNP
817	825	patients	patient	NNS
826	827	(	(	(
827	830	0/8	0/8	CD
831	834	and	and	CC
835	838	0/3	0/3	CD
838	839	,	,	,
840	852	respectively	respectively	RB
852	853	)	)	)
853	854	.	.	.

855	862	However	however	RB
862	863	,	,	,
864	875	stimulation	stimulation	NN
876	880	with	with	IN
881	885	IL-2	il-2	NN
886	894	resulted	result	VBD
895	897	in	in	IN
898	902	Jak3	Jak3	NNP
903	906	and	and	CC
907	912	STAT5	STAT5	NNP
913	928	phosphorylation	phosphorylation	NN
929	931	in	in	IN
932	936	both	both	CC
937	945	leukemic	leukemic	JJ
946	950	ATLL	atll	NN
951	956	cells	cell	NNS
957	960	and	and	CC
961	975	IL-2-dependent	il-2-dependent	JJ
976	981	lines	line	NNS
981	982	.	.	.

983	994	Furthermore	furthermore	RB
994	995	,	,	,
996	1006	expression	expression	NN
1007	1009	of	of	IN
1010	1015	SHP-1	shp-1	NN
1016	1027	phosphatase	phosphatase	NN
1028	1033	which	which	WDT
1034	1036	is	be	VBZ
1037	1038	a	a	DT
1039	1047	negative	negative	JJ
1048	1057	regulator	regulator	NN
1058	1060	of	of	IN
1061	1069	cytokine	cytokine	NN
1070	1078	receptor	receptor	NN
1079	1088	signaling	signaling	NN
1088	1089	,	,	,
1090	1093	was	be	VBD
1094	1098	lost	lose	VBN
1099	1101	in	in	IN
1102	1106	most	most	JJS
1107	1111	IL-2	il-2	NN
1112	1123	independent	independent	JJ
1124	1128	cell	cell	NN
1129	1134	lines	line	NNS
1135	1136	(	(	(
1136	1139	3/4	3/4	CD
1139	1140	)	)	)
1141	1144	but	but	CC
1145	1148	not	not	RB
1149	1151	in	in	IN
1152	1155	the	the	DT
1156	1164	leukemic	leukemic	JJ
1165	1169	ATLL	atll	NN
1170	1175	cells	cell	NNS
1176	1177	(	(	(
1177	1182	0/3).	0/3).	CD
1183	1190	Finally	finally	RB
1190	1191	,	,	,
1192	1195	the	the	DT
1196	1205	HTLV-I(+)	htlv-i(+)	JJ
1206	1212	T-cell	t-cell	NN
1213	1218	lines	line	NNS
1219	1220	(	(	(
1220	1223	313	313	CD
1223	1224	)	)	)
1225	1228	but	but	CC
1229	1232	not	not	RB
1233	1236	the	the	DT
1237	1244	control	control	NN
1244	1245	,	,	,
1246	1255	HTLV-I(-)	htlv-i(-)	JJ
1256	1262	T-cell	T-cell	NNP
1263	1268	lines	line	NNS
1269	1273	were	be	VBD
1274	1283	resistant	resistant	JJ
1284	1286	to	to	TO
1287	1296	rapamycin	rapamycin	NN
1297	1300	and	and	CC
1301	1304	its	its	PRP$
1305	1310	novel	novel	JJ
1311	1317	analog	analog	NN
1318	1321	RAD	RAD	NNP
1321	1322	.	.	.

1323	1325	We	we	PRP
1326	1334	conclude	conclude	VBP
1335	1339	that	that	IN
1340	1341	(	(	(
1341	1342	1	1	LS
1342	1343	)	)	)
1344	1350	HTLV-I	HTLV-I	NNP
1351	1360	infection	infection	NN
1361	1364	per	per	FW
1365	1367	se	se	FW
1368	1372	does	do	VBZ
1373	1376	not	not	RB
1377	1383	result	result	VB
1384	1386	in	in	IN
1387	1388	a	a	DT
1389	1401	constitutive	constitutive	JJ
1402	1417	phosphorylation	phosphorylation	NN
1418	1420	of	of	IN
1421	1424	the	the	DT
1425	1429	Jak3	jak3	NN
1429	1430	,	,	,
1431	1436	STAT3	STAT3	NNP
1436	1437	,	,	,
1438	1441	and	and	CC
1442	1447	STAT5	stat5	NN
1448	1456	proteins	protein	NNS
1456	1457	;	;	:
1458	1459	(	(	(
1459	1460	2	2	LS
1460	1461	)	)	)
1462	1471	malignant	malignant	JJ
1472	1486	transformation	transformation	NN
1487	1489	in	in	IN
1490	1492	at	at	IN
1493	1498	least	least	JJS
1499	1503	some	some	DT
1504	1509	cases	case	NNS
1510	1512	of	of	IN
1513	1517	ATLL	ATLL	NNP
1518	1522	does	do	VBZ
1523	1526	not	not	RB
1527	1534	require	require	VB
1535	1538	the	the	DT
1539	1551	constitutive	constitutive	JJ
1551	1552	,	,	,
1553	1556	but	but	CC
1557	1560	may	may	MD
1561	1568	require	require	VB
1569	1581	IL-2-induced	il-2-induced	JJ
1581	1582	,	,	,
1583	1593	activation	activation	NN
1594	1596	of	of	IN
1597	1600	the	the	DT
1601	1606	IL-2R	IL-2R	NNP
1607	1615	Jak/STAT	Jak/STAT	NNP
1616	1623	pathway	pathway	NN
1623	1624	;	;	:
1625	1628	and	and	CC
1629	1630	(	(	(
1630	1631	3	3	LS
1631	1632	)	)	)
1633	1638	there	there	EX
1639	1642	are	be	VBP
1643	1648	major	major	JJ
1649	1660	differences	difference	NNS
1661	1663	in	in	IN
1664	1670	T-cell	t-cell	NN
1671	1686	immortalization	immortalization	NN
1687	1699	mechanism(s)	mechanism(s)	NNS
1700	1705	which	which	WDT
1706	1712	appear	appear	VBP
1713	1715	to	to	TO
1716	1723	involve	involve	VB
1724	1729	SHP-1	shp-1	NN
1730	1733	and	and	CC
1734	1740	target	target	NN
1741	1750	molecules	molecule	NNS
1751	1754	for	for	IN
1755	1764	rapamycin	rapamycin	NN
1765	1768	and	and	CC
1769	1772	RAD	RAD	NNP
1772	1773	.	.	.